Garry E Menzel
CIK 1556064 · President and CEO · last filed 2025-06-12
Garry E Menzel is a President and CEO who has filed 35 SEC Form 4 insider transactions across 6 companies since 2012. The most recent filing, for BDTX, was dated Jun 12, 2025. Across all open-market trades the lifetime net is −$145.3K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $90.7K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$90.7K
6
35
-$145.3K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BDTX | Director | 51,825 | $1.75 | $90.7K | $0 | 7 | 2025-06-12 |
| STOK | Director | — | $29.82 | — | $0 | 6 | 2025-06-04 |
| Adaptimmune Therapeutics PLC (ADAP) Delisted | Director | 275,703 | $0.06 | $16.0K | -$43.4K | 5 | 2024-07-01 |
| TCR2 THERAPEUTICS INC. (TCRR) Delisted | President and CEO | 0 | $1.48 | $0 | -$101.9K | 15 | 2023-06-01 |
| DVA | Senior Vice President, Finance | — | $208.66 | — | $0 | 1 | 2013-09-11 |
| Regulus Therapeutics Inc. (RGLS) Delisted | COO & Executive VP, Finance | — | $8.16 | — | $0 | 1 | 2012-12-13 |
Recent Filings
35 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-12 | BDTX | Grant (A) | — | $0 | EDGAR |
| 2025-06-04 | STOK | Grant (A) | — | $0 | EDGAR |
| 2024-07-01 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-07 | STOK | Grant (A) | — | $0 | EDGAR |
| 2024-06-06 | BDTX | Grant (A) | — | $0 | EDGAR |
| 2023-07-10 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −47,702 | -$43.4K | EDGAR |
| 2023-07-05 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-07-03 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-15 | STOK | Grant (A) | — | $0 | EDGAR |
| 2023-06-01 | TCR2 THERAPEUTICS INC. (TCRR) Delisted | Disp (D) | −404,330 | $0 | EDGAR |